SuperworthKorsana Biosciences KRSA
- Market cap
- $20.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 11.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.9M
- −13% on a year ago
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Korsana Biosciences trades at 11.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.9M over the last twelve months, down 13% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $194K | $1.8M | $81K | $93K | $875K+351% | $1M−43% | $0 | $0 | |
| R&D | $580K−59% | $24K−100% | $44K−92% | $105K−69% | $81K−86% | $56K+133% | $36K−18% | $56K−47% | $348K+330% | $519K+827% | $730K+1928% | $0 |
| SG&A | $2.1M−31% | $1.8M−46% | $1.6M−42% | $1.3M−16% | $1.2M−42% | $1.2M−30% | $1.5M−5% | $1.7M+34% | $1.5M+24% | $1.3M+8% | $2.5M+65% | $1.8M+4% |
| −$6M+33% | −$1.8M−76% | −$1.6M−51% | −$1.4M−26% | −$1.1M−81% | $502K | −$1.5M−10% | −$1.7M+21% | −$1M−11% | −$838K | −$3.2M+120% | −$1.8M+6% | |
| Net income | $7.6M | −$1.7M−77% | −$1.5M−78% | −$1.3M−68% | −$723K | $530K | −$1.4M−7% | −$324K−76% | −$976K+35% | −$799K | n/a | n/a |
| $19.04 | −$4.83−79% | −$4.34−81% | −$3.71−71% | −$2.03 | $1.47 | −$3.92−10% | −$0.77−79% | −$2.10+3% | −$1.47 | −$5.32+36% | −$2.87+273% | |
| 398K+28% | 350.6K+13% | 356.3K+15% | 358.6K+10% | 360.9K−9% | 363.1K+4% | 365.1K+3% | 438.7K+22% | 460.7K+28% | 543.4K+50% | 600.7K+65% | 607.3K+38% |
EPS, diluted: 9 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Korsana Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KRSAKorsana Biosciences | $20.9M | n/m | n/a | 11.0× | −13% | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Korsana Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .